Clinical trial · Interventional
Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation
Remifentanil and Dexmedetomidine in Uterine Fibroid Ablation: a Comparative Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial aims to find a better drug concentration of Remifentanil in Uterine Fibroid Ablation. The main question it seeks to answer is: \[primary hypothesis 1\] Remifentanil concentration of 2.0 ng/mL provides better pain control in Uterine Fibroid Ablation. There is a comparison group in this study: Researchers will compare Remifentanil concentration of 1.0 ng/mL to see if provides similar pain control with fewer side effects. Participants will be separated into two groups, one group with a Remifentanil concentration of 2.0 ng/mL and the other 1.0 ng/mL. During uterine fibroid ablation, the patient\'s pain index will be recorded (using a Visual Analogue Scale (VAS) of 0\~10 points). We will also record vital signs during the procedure.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Fibroids (UF) | Uterine Corpus Leiomyoma | ALIAS | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| arm 1 | Drug | — | UNRESOLVED |
| arm 2 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- arm 1
- description
- During uterine fibroid ablation, the arm1 participant received Remifentanil \[ ALVOGEN® (2 mg/vial)\] 1.0 ng/mL via syringe infusion pump \[Perfusor® Space \| B. Braun\] as a pain treatment.
- interventionNames
- Drug: arm 1
- type
- ACTIVE_COMPARATOR
- label
- arm 2
- description
- During uterine fibroid ablation, the arm2 participant received Remifentanil \[ ALVOGEN® (2 mg/vial)\] 2.0 ng/mL via syringe infusion pump \[Perfusor® Space \| B. Braun\] as a pain treatment.
- interventionNames
- Drug: arm 2
Primary outcomes (1)
- measure
- Pain scores during uterine fibroid ablation
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Aged between 20 and 65 years old * American Society of Anesthesiology classification I\~III * Female patients diagnosed with uterine fibroids by obstetricians and gynecologists Exclusion Criteria: 1. Patients with heart disease (such as arrhythmia or severe ventricular dysfunction) 2. Patients with chronic kidney disease in stage III or above or dialysis patients 3. Long-term alcohol addiction or drug abuse 4. Patients with abnormal liver index or chronic hepatitis 5. Those who are allergic Remifentanil 6. Those who refuse to participate in the experiment
References
Publications (0)
Data not yet available